Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)
Public ClinicalTrials.gov record NCT03679676. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Randomized Controlled Trial Using Biologics to Improve Multi OIT Outcomes
Study identification
- NCT ID
- NCT03679676
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Stanford University
- Other
- Enrollment
- 130 participants
Conditions and interventions
Conditions
Interventions
- Omalizumab Drug
- Dupilumab Drug
- Placebo for Dupilumab Other
- Placebo for Omalizumab Other
Drug · Other
Eligibility (public fields only)
- Age range
- 4 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 4, 2020
- Primary completion
- Apr 14, 2025
- Completion
- May 1, 2025
- Last update posted
- May 28, 2026
2020 – 2025
United States locations
- U.S. sites
- 3
- U.S. states
- 1
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Los Angeles (UCLA) | Los Angeles | California | 90095 | — |
| Sean N. Parker Center for Allergy & Asthma Research at Stanford University | Palo Alto | California | 94304 | — |
| University of California San Diego (UCSD) | San Diego | California | 92123 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03679676, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 28, 2026 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03679676 live on ClinicalTrials.gov.